Abiopharma

Annual Reports and Related Documents:

Warrants Listing - Structured Warrants: Proposed Issue of Put Warrants

General Announcement: Responses to Substantive and Relevant Questions

Completion of the acquisition of control in Zafiros; equity investment and financing by The Phoenix

General Announcement: Prepared Remarks and Presentation for 1Q2026 Business and Operational Update

General Announcement: ANNUAL GENERAL MEETING TO BE HELD ON 29 APRIL 2026 - RESPONSE TO QUESTIONS FROM SHAREHOLDERS

Employee Stock Option/ Share Scheme: Notice of Transfer and Use of Treasury Shares

Change - Announcement of Cessation: Retirement of Independent Non-Executive Director - Mr Thanathip Vidhayasirinun

Share Buy Back - Daily Share Buy-Back Notice: Share Buy-Back

General Announcement: Responses to the Substantial and Relevant Questions for the AGM to be held on 30 April 2026

General Announcement: SGX Group welcomes Interactive Brokers Singapore as Derivatives Trading and Clearing Member

Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes

Annual Reports and Related Documents:

New Form DEFA14A - CHEMUNG FINANCIAL CORP <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0000763563-26-000013 <b>Size:</b> 200 KB

New Form ARS - Ralliant Corp <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0002041385-26-000037 <b>Size:</b> 14 MB